bioRxivPathologyPreprint
Human iPSC-derived liver organoids model multicellular tissue responses and therapeutic rescue in Wolman disease
Davide SelvestreliD, Caterina Da Rodda, Beatrice AnfusoiD, Marine LaurentiD, Annamaria AntonaiD, Alessia MattiviiD, Suresh VelnatiiD, Karin Hofmann, Luciano ContiiD, Deborah BonazzaiD, Fabrizio ZanconatiiD, Manuela MastronardiiD, Nicolò de ManziniiD, Natalia RossoiD, Rebecca BertolioiD, Andrea MarfogliaiD, Claudio Tiribelli, Marcello ManfrediiD, Daniela CapelloiD, Philippe DrabentiD, Luca L. FavaiD, Silvia PalmisanoiD, Giannino Del SaliD, Mario AmendolaiD, Giovanni SorrentinoiD
Abstract
Wolman disease (WD), the severe infantile form of lysosomal acid lipase deficiency, is a rare metabolic disorder caused by inactivating mutations in the LIPA gene. Although WD is characterized by profound hepatic dysfunction, experimental human systems capable of modelling multicellular liver pathology and supporting therapeutic testing remain limited. Here, we generated an isogenic human model of WD by introducing LIPA loss-of-function mutations into induced pluripotent stem cells and differentiating them into multicellular human liver organoids (HLO). LIPA-deficient HLO preserved hepatic lineage specification while recapitulating key biochemical and cellular features of WD, including loss of LIPA activity, lysosomal expansion, lipid accumulation, and activation of inflammatory and fibrogenic programs. Single-cell RNA sequencing resolved cell-type-specific disease states across hepatocyte-, stromal-, and biliary-like populations, revealing the emergence of a reactive biliary program consistent with ductular reaction, a complex tissue response associated with chronic liver injury. Importantly, this reactive biliary phenotype was supported by targeted gene-expression analysis in WD liver organoids and independently validated in liver tissue from mouse models and WD patients. Isolated LIPA-deficient cholangiocyte organoids failed to reproduce the DR-associated program, indicating that this response depends on multicellular interactions within the hepatic microenvironment rather than on biliary cell-autonomous dysfunction alone. Consistently, hepatocyte-directed AAV-mediated restoration of LIPA expression attenuated metabolic stress, inflammatory and fibrogenic programs, and suppressed ductular reaction both in organoids and in vivo. Together, these findings establish multicellular human liver organoids as a physiologically relevant platform for modelling emergent tissue-level responses in WD and for evaluating therapeutic rescue strategies in a human context.
- organism: human
- assay: scRNA-seq
- research focus: cell type annotation
- research focus: differential expression
- research focus: drug response / drug discovery
- approach: experimental assay
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Retinoids rescue ceruloplasmin secretion and alleviate oxidative stress in Wilson's disease-specific hepatocytes
D. Song, G. Takahashi, … Y. Hayashi·Human Molecular GeneticsPeer-reviewed·Oct 28, 2022
- Generation of liver organoids from human induced pluripotent stem cells as liver fibrosis and steatosis models
H. Y. Tsang, P. H. Y. Lo, K. K. H. Lee·bioRxiv·Jun 29, 2021
- Hepatic Differentiation of Human Pluripotent Stem Cells into Functional In Vitro Models Recapitulating Native Liver Complexity for MASLD Modelling
Saloni Sainger, Anshul Chikara, … Santosh Mathapati·bioRxiv·Jul 12, 2026
- Development of alcoholic liver disease model for drug evaluation from human induced pluripotent stem cell derived liver organoids
Zhiwei Feng, Bingrui Zhou, … Jun Xie·bioRxiv·Mar 10, 2024
- Novel cytometry-based characterization of lysosomal storage disease affected patient's cells
Marine Laurent, Jérémie Cosette, … Mario Amendola·bioRxiv·Mar 18, 2025
- Novel 3D Approach to Model Non-Alcoholic Fatty Liver Disease using human Pluripotent Stem Cells
C. M. Morell, S. G. Tilson, … L. Vallier·bioRxiv·Feb 7, 2024